
Sophia Gaulkin
Articles
-
Jan 24, 2025 |
mondaq.com | Sophia Gaulkin |Riette van Laack |Riëtte van Laack
Readers of this blog likely are familiar with the ongoing, oftencontentious battle over the labeling of plant-based foods (see,e.g., here, here, and here). Nearly two years after FDA issued draft guidance on Labeling of Plant-Based Milk Alternatives andVoluntary Nutrient Statements, on January 6, 2025, FDA releaseddraft guidance document on plant-based labeling, Labeling Plant-Based Alternatives to Animal-DerivedFoods.
-
Jan 20, 2025 |
thefdalawblog.com | Riette van Laack |Riëtte van Laack |Sophia Gaulkin
Readers of this blog likely are familiar with the ongoing, often contentious battle over the labeling of plant-based foods (see, e.g., here, here, and here). Nearly two years after FDA issued draft guidance on Labeling of Plant-Based Milk Alternatives and Voluntary Nutrient Statements, on January 6, 2025, FDA released draft guidance document on plant-based labeling, Labeling Plant-Based Alternatives to Animal-Derived Foods.
-
Jan 17, 2025 |
mondaq.com | Sophia Gaulkin |Riette van Laack |Riëtte van Laack
On January 6, 2025, FDA released two final guidance documents onfood allergens: Questions and Answers Regarding Food Allergens,Including the Food Allergen Labeling Requirements of the FederalFood, Drug, and Cosmetic Act (Edition 5), and Evaluating the Public Health Importance of FoodAllergens Other Than the Major Food Allergens Listed in the FederalFood, Drug, and Cosmetic Act.
-
Jan 14, 2025 |
thefdalawblog.com | Riette van Laack |Riëtte van Laack |Sophia Gaulkin
On January 6, 2025, FDA released two final guidance documents on food allergens: Questions and Answers Regarding Food Allergens, Including the Food Allergen Labeling Requirements of the Federal Food, Drug, and Cosmetic Act (Edition 5), and Evaluating the Public Health Importance of Food Allergens Other Than the Major Food Allergens Listed in the Federal Food, Drug, and Cosmetic Act.
-
Apr 16, 2024 |
thefdalawblog.com | Sophia Gaulkin
On April 10, the Fourth Circuit unanimously affirmed a summary judgment ruling for the Centers for Medicare & Medicaid Services (CMS) regarding the agency’s definitions of “line-extension drug” and “new formulation” for purposes of determining rebates that drug manufacturers may owe the Medicaid Drug Rebate Program (MDRP). Vanda Pharmaceuticals, Inc. v. Centers for Medicare and Medicaid Servs., No. 23-1457 (4th Cir. Apr. 10, 2024).
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →